CD99 gene encodes two distinct proteins, produced by alternative splicing of CD99 gene transcript. Full-length CD99 isoform (CD99wt) is formed by an extracellular domain, followed by a transmembrane domain and a 36 amino-acid intracytoplasmic domain, which is partially deleted in the truncated, short form (CD99sh). A differential expression of these two CD99 molecules can lead to distinct functional outcomes in lymphocytes. To investigate the functional effects of CD99 molecules on malignancy, forced overexpression of the two CD99 isoforms was induced in osteosarcoma and prostate cancer cells. The two isoforms exhibited opposite functions: the major form dramatically inhibits anchorage-independent growth, anoikis resistance, migration and metastasis, whereas the CD99sh remarkably favours the phenomena. A mechanistic analysis of CD99-transfected osteosarcoma cells points to involvement of c-Src family kinase activity in regulating CD99 functions in malignancy. Ser168 residue of CD99 plays a pivotal role in the reversion of the malignant phenotype. Our findings highlight the involvement of CD99 in crucial processes of cancer malignancy, serving as a curtain raiser for this, so far neglected molecule. In addition, a dualistic role for the two CD99 isoforms was shown in agreement with what was observed for other cell adhesion molecules.
Introduction
CD99 is a transmembrane glycoprotein with no homology with other known proteins except for the Xga protein (Fouchet and Gane, 2000) that has been implicated in cell adhesion, apoptosis, differentiation of T cells and thymocytes (Bernard et al., 1997; Alberti et al., 2002) , migration of monocytes (Schenkel et al., 2002) and intercellular adhesion between lymphocytes and endothelial cells (Bernard et al., 2000) . In pathological conditions, the triggering of CD99 results in the induction of cell-cell adhesion and apoptosis of Ewing's sarcoma cells (Sohn et al., 1998; Scotlandi et al., 2000; Cerisano et al., 2004) . Moreover, it has recently been found that CD99 downregulation is essential in osteosarcoma to express full malignancy (Manara et al., 2006) . However, globally, the functions of CD99 in malignancies are still poorly understood.
CD99 gene encodes two distinct proteins, produced by alternative splicing of the CD99 gene transcript (Hahn et al., 1997) . The structure of the full-length CD99 isoform (CD99wt) is formed by an extracellular domain, which is glycosylated with O-linked sugar residues, followed by a transmembrane domain and a 36 aminoacid intracytoplasmic domain. The truncated, short form (CD99sh) results from an alternative splicing of CD99-encoding mRNA that gives rise to a deletion in its intracytoplasmic fragment. In particular, the CD99sh transcript contains an 18-bp insertion at the boundary of exons 8 and 9 of the CD99 gene, which introduces an in-frame stop codon that generates truncated polypeptide (Hahn et al., 1997) . The production of CD99sh transcript is conserved in monkey, suggesting that the CD99-truncated molecule has functional significance. Interestingly, the alternative spliced isoforms of CD99 transcripts are differentially expressed in a celltype-specific manner among haematopoietic cells, with CD99wt predominantly expressed (Bernard et al., 1997; Hahn et al., 1997) . Peripheral T cells display an exclusive expression of the full-length isoform, whereas doublepositive thymocytes express both isoforms. Moreover, the differential expression of these two CD99 molecules can lead to distinct functional outcomes. The expression of the long form in a CD99-deficient Jurkat T-cell line is sufficient to promote CD99-induced cell adhesion, whereas coexpression of the two isoforms is required to trigger T-cell death (Bernard et al., 1997) . On B cells, the minor, splicing form of CD99 inhibited homotypic adhesion, while the activation of the long CD99wt form promoted cell-cell adhesion, indicating that the CD99 gene produces two distinct proteins with opposite functions in the adhesion processes of lymphocytes (Hahn et al., 1997) . CD99 is differentially expressed in neoplasms, with a strong expression in some paediatric tumours, such as Ewing's sarcoma and acute lymphoblastic leukaemia cells (Ambros et al., 1991; Scotlandi et al., 1996; Dworzak et al., 2004) , and a low, but broad, distribution in many other neoplastic cell types. However, it remains to be elucidated whether the CD99 expression may even display specific role/s in malignant phenotypes. Indeed, we recently found that the forced expression of the long CD99wt form acts as an oncosuppressor in osteosarcoma (Manara et al., 2006) , whereas in Ewing's sarcoma, the abrogation of CD99 expression is required for in vitro malignant reversion (Kreppel et al., 2006) , pointing out a dual role of the molecule as an oncosuppressor or oncogene depending on the cellular context. Here we extended the analysis to the functional effects of the truncated variant of CD99. A forced expression of the two CD99 isoforms was induced in both human osteosarcomas and prostate cancer cells, and in vitro and in vivo behaviour of selected transfectants was studied accordingly, together with molecular mechanisms responsible for malignancy modulation.
Results

CD99 isoforms dictate different in vitro behaviour of osteosarcoma and prostate cancer cells for parameters related to malignancy
The transfection of cDNAs encoding for long or short form of CD99 was carried out in the U-2 OS osteosarcoma and PC3 prostate cancer cell lines. These two models, a sarcoma and a carcinoma tumour, were chosen with the intent to obtain a more general view of CD99's role. The prostate cell carcinoma was selected because: (1) it leads to lung and bone metastasis, so that metastasis occurs in the same tissue microenvironments in which osteosarcoma cells grow and metastatise. (2) Prostate bone metastases are generally osteoinductive lesions and prostate cancer cells have been described to display tumour plasticity and acquire features of osteoblastic cells (Huang et al., 2005) . Therefore, although the two tumours are certainly very different for histogenesis, they may share common biological features. Stable transfectants were selected in G418 and chosen for CD99 isoform expression on cell surface (Figure 1a and b). U-2 OS clones transfected with the long CD99wt isoform had already been described (Manara et al., 2006) . Here we report the data of U-2/ CD99wt57 or U-2/CD99wt136 as additional controls to highlight the effects of the truncated CD99 variant in osteosarcoma cells. Expression of the two CD99 forms slightly reduced in vitro growth ability of transfectants in monolayer, without remarkable differences between clones (Figure 2a) . On the contrary, the two isoforms dictated opposite effects when anchorage-independent growth was analysed (Figure 2b ). CD99wt transfectants showed a significant reduction in the size and number of colonies, whereas cells overexpressing CD99sh resulted in larger and more abundant colonies in soft agar. The different pattern of growth in soft agar of CD99-transfected cells appeared to be caused by varying sensitivity to anoikis (detachment-induced apoptosis). Indeed, cell survival was severely reduced (Figure 2c ) and sensitivity to anoikis increased (Figure 2d ) in U-2/ CD99wt, but not in U-2/CD99sh, when cells were prevented to adhere. The expression of the two CD99 isoforms also induced contrasting abilities in cell migration and adhesion. Forced expression of truncated CD99 interfered with spontaneous aggregation of U-2 OS osteosarcoma cells, by reducing cell-cell adhesion (Figure 3a) , and with migration, by dramatically increasing the migration ability of CD99sh-transfected osteosarcoma (Figure 3b ). Similar evidences were obtained in prostate cancer cells, the long CD99 isoform significantly reducing, while truncated form increasing cell migration (Figure 3c ). Higher levels of actin expression and organization were observed in the lessmigrating U-2/CD99wt cells compared to cells expressing truncated CD99 isoform and parental cell line (Figure 3d ) to confirm the induction of a less-mobile phenotype after expression of the long molecule. In addition, differential expression of the two CD99 isoforms affected the interactions of cells with extracellular matrix (ECM) components. CD99wt increases adhesive ability of cells on collagen I, laminin and fibronectin, whereas overexpression of the truncated isoform generally reduces adhesion to ECM components with the exception of fibronectin (Figure 3e ). Modulation of adhesive properties does not seem to be attributable to significant changes in integrin b1 or a V b 3 expression pattern (data not shown). To rule out the possibility that a very high ectopic expression of CD99 forms may lead to effects that are not physiologically relevant, we also studied the behaviour of two clones showing an intermediate level of CD99 isoform expression (Supplementary Figure 1) . Their migration and growth abilities in soft agar overlapped the behaviour of the previously selected clones.
CD99 isoforms and metastases
We have previously reported a significant reduction in local tumour and lung metastasis formation following forced expression of the CD99wt isoform in U-2 OS cells (Manara et al., 2006) . Herein, we extend the study to prostate cancer, showing a wider role for CD99wt in the abrogation of metastasis. Indeed, in both osteosarcoma and prostate cancer, cells overexpressing the long CD99wt isoform inhibited and delayed formation of lung or bone metastases (Figure 4a ). On the contrary, overexpression of the truncated isoform of CD99 slightly increased metastatic potential of U-2 OS cells (Figure 4b and c). It is interesting to note that the contrasting functions of CD99 isoforms are strictly related to metastasization, since similar reductions in the tumorigenic ability of U-2 OS (data not shown) and decreased in vitro proliferation rates were observed in all the transfectants.
Endogenous expression of CD99 isoforms was examined in a panel of osteosarcoma cell lines. We confirmed by quantitative PCR that the expression of CD99 is lower than in normal osteoblasts (Figure 4d ). However, despite the generally low level of expression, we were able to discriminate between the two forms by using specific primers (Figure 4e ). Although the CD99wt isoform occurred to a greater extend, as expected, we find at least one osteosarcoma cell line in which the splice variant is prevalent. Interestingly, the cell lines in which CD99 is barely expressed (U-2 OS) or the CD99wt form exists at lower level than CD99sh (IOR/OS9) display higher metastasis ability (incidence of lung metastasis in mice was 90% and 100% in U-2 OS and IOR/OS9, respectively). On the contrary when the CD99wt is prevalent, such as in Saos-2 and SARG, the malignancy is reduced (incidence of lung metastasis was 50 and 0%, respectively) (Scotlandi et al., 1993) . The reversal function/s of CD99wt were also confirmed by U-2 OS transfectants coexpressing both long and truncated forms in almost equal quantities (Figure 5a ). In general, the clones coexpressing the two CD99 forms behave in a similar manner to CD99wt transfectants with respect to cell growth in soft agar, migration (Figure 5b and c) and metastasis. U-2/CD99 wt/sh 8 did not manifest lung metastases in 10 mice and U-2/CD99 wt/sh 45 presented metastases in only two out of 10 mice (median 0, range 0-30), indicating that the major form acts dominantly with respect to the truncated one when their reciprocal level of expression is similar. The intra-cytoplasmic segment of CD99 molecule deleted in the truncated form should,
PC-3 PC-3/Empty CD99 isoforms differently affect tumour metastasis K Scotlandi et al therefore, be important for the delivery of an antimetastatic signal.
Differences in migration and metastasis are related to CD99 ser168
In order to identify the residues of the CD99 molecule responsible for the malignant reversion, U-2 OS cells transfected with mutated forms of the protein were obtained. Plasmids expressing CD99 molecules that carry appropriate substitutions in the potentially important residues Tyr146 (Y146) and Ser168 (S168) were created. Tyr146 is located in the intracellular residue common to the two isoforms, whereas Ser168 is in the cytoplasmic portion of the molecule that is missing in the truncated, short CD99 isoform. Two clones for each type of mutation (identified as U-2/ CD99mutY146 or U-2/CD99mutS168, respectively), with equivalent expression of the extracellular domain of CD99, were selected ( Figure 6a ). We found that CD99 mutation at Ser168 level greatly increased migration and anchorage-independent growth of U-2 OS cells ( Figure 6b and c), in keeping with what was observed for CD99sh clones. Cells expressing CD99 mutated at Tyr146 exhibited similar behaviour as compared to those expressing long CD99wt isoform: decreased migration (Figure 6b ), reduced the ability to grow in soft agar (Figure 6c ), and abrogation of lung metastasis ( Figure 6d ). On the contrary, a similar number of experimental lung metastases were observed in mice injected with parental or U-2/CD99mutS168 cells ( Figure 6d ). Consistent with this, Ser168 appears as an important CD99 motif for the inhibition of migration and metastasis in U-2 OS osteosarcoma cells. Its lack, either due to specific mutations or due to a complete absence as in CD99sh clones, results in the disappearance of the negative impact of CD99wt, whereas its presence, either in cells expressing only CD99wt or coexpressing the two isoforms, is sufficient for the inhibition of migration and metastasis.
c-src kinase activity is involved in CD99 functions and oppositely affected by the two isoforms Recently, we identified at least two molecules interacting with CD99 in U-2 OS cells, caveolin-1 and c-Src (Manara et al., 2006) . C-Src is largely involved in pathophysiology of osteoblasts (Marzia et al., 2000) and CD99 isoforms differently affect tumour metastasis K Scotlandi et al prostate cancer (Jee et al., 2003; Recchia et al., 2003) along with the significant role that it plays in the regulation of crucial processes implicated in the pathogenesis and progression of tumours, such as cell cycle, migration, resistance to anoikis and anchorage independence (Irby and Yeatman, 2000) . Therefore, we evaluated its role as a possible mediator of CD99 functions. Immunoprecipitation of c-Src was observed the kinase domain upregulates the enzyme activity, whereas the phosphorylation of Tyr527 in carboxyterminal tail renders the enzyme less active. In Manara et al. (2006) , we hypothesized that CD99wt oncosoppressor role is mediated by caveolin-1, which is known to act as an allosteric inhibitor of c-Src. Here we confirmed that caveolin-1 expression is upregulated only in U-2/CD99wt but not in cells expressing the truncated form (Figure 7c) . Consistent with this, the level of c-Src autophosphorylation was significantly reduced in U-2/CD99wt and U2-/CD99mutY146, while U2-/ CD99sh and U-2/CD99mutS168 displayed an even higher level of phosphorylation than parental and empty vector-transfected cells (Figure 7d and e) . Involvement of c-Src as mediator of CD99 intracellular signalling was confirmed by two inhibitors of c-Src kinase family with different mechanisms of action. Both the PP2 compound and herbimycin significantly suppressed the motility of parental cells as well as of clones expressing truncated CD99 isoform or U-2/CD99mutS168, but not U-2/CD99wt and U-2/ CD99mutY146 (Figure 7f ). In addition, a rescue experiment was performed in CD99wt clones by using pYEEI, a peptide that, by competing with the negative regulatory role/s of SH2 domain, represents a mean of activating endogenous c-Src activity (Wijetunge and Hughes, 1996; Porter et al., 2000) . Indeed, exposure of U-2/CD99wt cells to pYEEI restored c-Src kinase activity ( Figure 7g ) and accordingly their motility (Figure 7h ).
Discussion
Purpose of this study was to gain new insights into the biological role of CD99 in neoplasia. In lymphocytes, CD99 can be expressed either as the full-length unspliced form (CD99wt) or as the short variant resulting from alternative splicing (CD99sh). Moreover, the differential expression dictates different functions (Hahn et al., 1997; Alberti et al., 2002; Jung et al., 2002) . Although limited information is available with respect to this, the general idea is that both isoforms serve a functional role in the immune system. The novelty of this study is related to the observation that (1) CD99 isoforms dictate different functions also in malignancy, oppositely affecting crucial biological processes both in osteosarcoma and in prostate cancer cells; (2) the two isoforms can either activate or repress c-Src family kinase activity, thereby providing at least a conceptual basis for their dualistic functions in modulating cell migration, anchorage-independence growth and metastasis. In particular, we showed that long CD99 isoform overexpression significantly decreased the number and size of cell colonies in soft agar, increased sensitivity to anoikis, that is, detachment-induced apoptosis, and furthermore, resulted in a decrease in cell migration. Strikingly in contrast, expression of the truncated form dramatically increased anchorage-independent growth and cell migration. A different pattern of cell adhesion properties and actin organization completed the list of biological features that are differentially regulated by CD99 isoform expression. CD99wt-expressing cells showed higher adhesion to collagen I, laminin and fibronectin and more organized actin filaments, in keeping with the less-migrating phenotype. It is worth noting here that all these in vitro features exhibit a strong correlation with metastases. Indeed, different growth in anchorage independence, sensitivity to anoikis, migration and cell adhesion may all contribute to and most often are the cause of the different metastatic behaviour of cells expressing alternative CD99 isoforms. The almost complete abrogation of metastasis following expression of CD99wt in prostate cancer cells further reinforce our previous observations in osteosarcoma (Manara et al., 2006) and clearly point out that CD99wt can function as an oncosuppressor in a wider group of tumours. Besides osteosarcoma and prostate cancer, previous studies in lymphomas reported how in vitro downregulation of CD99wt in B lymphocytes generates cells with Hodgkin and Reed-Sternberg phenotype, therefore implicating the association of loss of CD99 in Hodgkin disease pathogenesis (Kim et al., 2000) . In pancreatic endocrine neoplasms carcinoma, CD99wt has been found to be downregulated in malignant lesions as compared to the benign and its loss elucidated a negative prognostic value (Maitra et al., 2003; Goto et al., 2004) . Similarly, in gastric adenocarcinoma, downregulation of CD99wt was associated with dedifferentiation of tumour cells and/ or MMP-2 overexpression (Jung et al., 2002) . Therefore, the regulation of CD99wt expression may play a general functional role in tumorigenesis or tumour progression, serving as tumour suppressor molecule. With the exception of some paediatric tumours such as Ewing's sarcoma and acute lymphoblastic leukaemia (Ambros et al., 1991; Dworzak et al., 2004) , which express high levels of the protein, loss rather than overexpression may substantially contribute to malignancy. Here, we also demonstrated that the Ser168 residue of CD99 molecule is required for the oncosuppressor functions of CD99wt. Cells lacking Ser168 residue for specific mutations or deletion of larger intracytoplasmic fragment, such as in the truncated CD99 isoform, regain or enhance their migration and metastasis ability. Indeed, the expression of the truncated isoform of CD99 appears to favour cancer malignancy by increasing anchorage-independence growth, resistance to anoikis and metastasis. The favouring role of the splice variant of CD99 in malignancy has been very recently extended also to breast cancer cells (Byun et al., 2006) , indicating a more common role for this molecule than it was thought. Owing to a quite restrict pattern of expression, CD99 has been limitedly studied. Nevertheless, differential expression and functions of alternative splicing products is a physiological and pathological feature of many other cell adhesion molecules. As one of the cell adhesion molecules, CD99 isoforms were also found to be differentially expressed among various human tumour and normal cell lines (Hahn et al., 1997) . 
CD99 isoforms differently affect tumour metastasis K Scotlandi et al
From a mechanistic point of view, it is interesting that the two isoforms of CD99 display similar, inhibitory effects on growth in monolayer and tumorigenicity, while dictate opposite behaviour with respect to anchorage-independence growth, either in vitro (growth in soft agar, resistance to anoikis) and in vivo. These effects have been found to be very similar to those reported for c-Src kinase activity, which did not affect the growth of carcinoma cells xenografts in nude mice, but was shown to be strictly involved in cell metastasis (Boyer et al., 2002) . Accordingly, we observed a reduction of c-Src kinase activity in osteosarcoma CD99wt transfectants, whereas in CD99sh clones the c-Src kinase activity was even higher than in parental cell lines. Both the CD99 isoforms co-immunoprecipitated with c-Src, but only CD99wt upregulated and colocalized with caveolin-1. In Manara et al. (2006), we postulated that by enhancing caveolin-1 and recruiting c-Src to caveolin, CD99wt contributes to maintain c-Src in an autoinhibitory conformation. This idea is here further supported by the features of CD99sh, which despite being able to physically interact with c-Src, did not form the complex CD99-caveolin-1-c-Src and thereby did not decrease c-Src kinase activity. The fact that CD99wt, in cooperation with caveolin-1, acts as an allosteric inhibitor of c-Src was also supported by the use of pYEEI, a peptide that has been shown to increase c-Src activity by competing with the c-Src tail (Ayrapetov et al., 2006) . By disrupting the intimate interactions between Src and the CD99-caveolin-1 complex, which are necessary to maintain the enzyme in an inhibited conformation, pYEEI restored the Src kinase activity in CD99wt cells and their motile phenotype. The effect/s of c-Src kinase activity on the migration of In vitro features of clones coexpressing both CD99 isoforms. Relative expression of CD99 isoforms in U-2 OS clones by western blot (a). Growth in soft agar of CD99-co-transfected clones. Data are expressed as means of 4-6 plates7s.e. *Po0.05; **Po 0.001, Student's t-test, with respect to U-2 OS parental cells (b). Migration ability of CD99-co-transfected clones. Each column represents the mean7s.e. of three independent experiments. *Po0.05; or **Po0.001, Student's t-test (c).
CD99 isoforms differently affect tumour metastasis K Scotlandi et al CD99-transfected cells was also confirmed by the use of c-Src inhibitors, and it is likely responsible of their metastatic behaviour. A very recent paper also invoked c-Src functional involvement for CD99 intracellular signalling in breast cancer (Byun et al., 2006) . However, the authors focused on downstream mediators activated by CD99 engagement; therefore, our study provides complementary rather than coincidental information on the role of this so far neglected molecule in tumour biology.
In conclusion, our data indicate that CD99wt and, in particular, the residue Ser168 of the molecule, plays a noteworthy role in the modulation of cancer malignancy acting as a potent suppressor of migration and metastatization. Moreover, an increased or decreased c-Src kinase activity was observed in cells alternatively expressing the two CD99 isoforms indicating this molecule as a crucial mediator of CD99 functions. 
Materials and methods
Cell lines and transfection
Osteosarcoma cell lines U-2 OS, SaoS-2 and MG-63 and the prostate cancer cell line PC3 were obtained from the American Type Culture Collection (Rockville, MD, USA). All the other osteosarcoma cell lines (SARG, IOR/OS7, IOR/OS9, IOR/ OS14) were obtained at the Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli, Bologna, Italy, and previously characterized (Benini et al., 1999) . pcDNA3 vector was used to construct plasmids expressing full-length CD99, the truncated form (shCD99) or the mutated molecules carrying mutations at the residue Ser168 or Tyr146 of the molecule. Stable transfectants expressing CD99 isoforms were obtained by using calcium phosphate transfection method. Cells transfected with the empty vector pcDNA3 were also used as negative controls. Transfectants were selected in Iscove's modified Dulbecco's medium (IMDM) containing 10% FBS and 500 mg/ml neomycin (Sigma, St Louis, MO, USA) and maintained in selective medium for a maximum of eight in vitro passages before the in vitro and in vivo characterization.
Cytofluorometric analysis of CD99 and integrins
Expression of CD99 and integrins was analysed by indirect immunofluorescence as previously described (Manara et al., 2006) .
Analysis of growth features
Doubling time in monolayer was determined by daily harvesting of cells after seeding of 20 000 cells/cm 2 in IMDM 10% fetal bovine serum (FBS). Cell viability was determined by Trypan blue dye exclusion. Detection and quantification of apoptotic cells was obtained by the flow cytometric analysis (FACSCalibur, Becton Dickinson, San Jose, CA, USA) of annexin-V-FITC-labelled cells according to the manufacturer's instructions (Medical & Biological Laboratories, Naka-ku Nagaya, Japan). Anchorage-independent growth and Poly-HEMA (2-Hydroxyethylmethacrylate) Assay experiments were performed as previously described (Manara et al., 2006) . Homotypic adhesion, ECM adhesion and motility assay Homotypic adhesion assay was performed as previously described (Cerisano et al., 2004) . The adhesive ability was analysed by using the CytoMatrix cell adhesion strips coated with human collagen type IV, vitronectin, fibronectin, laminin or collagen type I (Chemicon International, Temecula, CA, USA) according to the manufacturer's instructions.
Motility assay was performed using Trans-well chambers (Costar, Cambridge, MA, USA). 10 5 cells in IMDM plus 10% FBS with or without different c-Src inhibitors (PP2, 5 mM; PP3 5 mM; Herbimycin, 4 mM, all provided by Calbiochem, San Diego, CA, USA) or the Src activator pYEEI (100 mM, BIOMOL Research Laboratory, Plymouth Meeting, PA, USA) were seeded in the upper compartment, whereas IMDM plus 10% FBS was placed in the lower compartment of the chamber. Experiments were performed in triplicate.
Fluorescence on adherent fixed cells Immunofluorescence was performed on adherent cells grown on coverslips for 48 h and fixed in 4% para-formaldehyde, and permeabilized with 0.15% Triton X-100 in phosphate buffered saline (PBS), or in methanol/acetone 3:7 and incubated with the following antibodies: a-CD99 O13 (Signet, Dedham, MA, USA); a-Caveolin-1 (BD Transduction Labs, Lexington, KY, USA); a-phospho-c-Src tyr416 (New England Biolabs, Cell Signalling Technology, Inc., Beverly, MA, USA) or FITC-conjugated phalloidin (Sigma).
RNA extraction and reverse transcription-PCR Total RNA was extracted using the TRIzol extraction kit (Invitrogen Ltd, Paisley, UK). For the quantification of the two CD99 isoforms, mRNA was extracted using QIAGEN Oligotex Direct mRNA Micro Kit (QIAGEN, Hilden, Germany). In total, 500 mg of total RNA for each sample were reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA).
Quantitative real-time reverse transcription-PCR For the quantitative detection of CD99, a specific TaqMan Gene Expression Assay was purchased from Applied Biosystems (Assay ID Hs00365982_m1, Ref. Seq. NM_002414.3). Human GAPDH was used as endogenous control; TaqManspecific primers and probes were designed by using Primer Express software (Applied Biosystems) as follows (all 5 0 -3 0 direction): forward GAAGGTGAAGGTCGGAGTC, reverse GAAGATGGTGATGGGATTTC, probe: FAM-GAA GCT TCCCGTTCTCAGCC. All PCR reactions were performed by using ABI PRISM 7900 Sequence Detection System (PE Applied Biosystems). The relative mRNA expression of CD99 was determined by comparative Ct method with respect to a calibrator, consisting of a human osteoblast primary culture. For the absolute quantification of the long (CD99wt) and short (CD99sh) CD99 isoforms, the following primers were used (all 5 0 -3 0 ): forward GTGATCCCCGGGATTGTG; CD99wt reverse CTATTTCTCTAAAAGAGTACG; CD99sh reverse CCTAGGTCTTCAGCCATC.
Western blotting and immunoprecipitation analysis
Western blotting and immunoprecipitation experiments were performed as previously described (Manara et al., 2006) The following antibodies were used: anti-CD99 12E7 antibody (DAKO, Glostrup, Denmark; 1:10 000 dilution), anti-phospho-Src tyr416 and anti-c-Src (Cell Signalling Technology; 1:1000 dilution). Anti-mouse or anti-rabbit secondary antibodies conjugated to horseradish peroxidase were from Amersham (Amersham Place, Buckinghamshire, UK).
Determination of src phosphorylation by cell-based enzyme-linked immunosorbent assay To determine the phosphorylation status of Src, cells were seeded into 96-well clear flat bottom TC-treated microplates (Corning Costar) at the density of 5 Â 10 3 cells/well in IMDM 10% FBS. At 48 h after seeding, cells were fixed in 4% formaldehyde at room temperature and thereafter used to measure Src phosphorylation using a cell-based CASE enzyme-linked immunosorbent assay kit (SuperArray) according to the manufacturer's instructions. The absorbance readings were normalized to relative cell number as determined by a cell staining solution.
Tumorigenic and metastatic ability in athymic mice Athymic 5 weeks old Crl:nu/nu (CD-1) BR mice (Charles River Italia, Como, Italy) were used. Tumorigenicity was determined after s.c. injection of 5 Â 106 cells, whereas metastasization was evaluated after i.v. injection of 2 Â 106 cells. Tumour growth and bone metastases were assessed once a week by measuring tumour volume. The number of pulmonary metastases was determined 2 months after cell inoculation by counting with a stereomicroscope after staining with black India ink. Experimental procedures were approved by the local ethical committee.
Statistical analysis
Differences among means were analysed using Student's t-test. Fisher's exact test was used for frequency data.
